OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025

OSE Immunotherapeutics Reports its Cash Position
as of June 30, 2025

Nantes, France, September 25, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (SGMX:OSEp(SGMX:OSEpOSEpsSGMX:OSEptSGMX:OSEprSGMX:OSEpoSGMX:OSEpnSGMX:OSEpgSGMX:OSEp>SGMX:OSEpISGMX:OSEpSSGMX:OSEpISGMX:OSEpNSGMX:OSEp:SGMX:OSEp SGMX:OSEpFSGMX:OSEpRSGMX:OSEp0SGMX:OSEp0SGMX:OSEp1SGMX:OSEp2SGMX:OSEp1SGMX:OSEp2SGMX:OSEp7SGMX:OSEp1SGMX:OSEp7SGMX:OSEp3SGMX:OSEp;SGMX:OSEp SGMX:OSEpMSGMX:OSEpnSGMX:OSEpeSGMX:OSEpmSGMX:OSEpoSGMX:OSEp:SGMX:OSEp SGMX:OSEpOSGMX:OSEpSSGMX:OSEpESGMX:OSEp)SGMX:OSEp, Mnemo: OSE)) reports its cash position as of June 30, 2025. Due to the Company’s Annual General Meeting being rescheduled to September 30, 2025, and to allow shareholders to first approve 2024 financial statements, the full 2025 half-year interim financial results will be published on October 15, 2025.

Update on AbbVie Partnership related to ABBV-230

The Company initially expected the initiation of Phase 1 trial of ABBV-230 and the related milestone payment in late 2025. Based on current discussions with its partner, the Company now anticipates a delay in the development timeline.

As the Company has no control over the start of this trial, and in line with the principle of prudence, it has chosen to exclude from its current cash projections the related milestone payment from AbbVie.

Cash Position as of June 30, 2025

As of June 30, 2025, OSE Immunotherapeutics’ cash position totalled €41.6 million, compared to €64.2 million …

Full story available on Benzinga.com